[go: up one dir, main page]

AR058749A1 - Inhibidores de c3-convertasa para la prevencion y el tratamiento de la degeneracion macular relacionada con la edad en pacientes con variantes de riesgo de factor h de complemento - Google Patents

Inhibidores de c3-convertasa para la prevencion y el tratamiento de la degeneracion macular relacionada con la edad en pacientes con variantes de riesgo de factor h de complemento

Info

Publication number
AR058749A1
AR058749A1 ARP060105794A ARP060105794A AR058749A1 AR 058749 A1 AR058749 A1 AR 058749A1 AR P060105794 A ARP060105794 A AR P060105794A AR P060105794 A ARP060105794 A AR P060105794A AR 058749 A1 AR058749 A1 AR 058749A1
Authority
AR
Argentina
Prior art keywords
risk
polymorphism
amd
patient
age
Prior art date
Application number
ARP060105794A
Other languages
English (en)
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of AR058749A1 publication Critical patent/AR058749A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Métodos para identificar a un paciente en riesgo de desarrollar DMRE mediante la identificacion de la presencia del polimorfismo Y402H o de otras variantes de riesgo en el gen el factor H de complemento. Además métodos para el tratamiento de personas que tienen DMRE o que se encuentran en riesgo de desarrollar DMRE como resultado e poseer el polimorfismo Y402H u otras variantes de riesgo en el gen del factor H de complemento. Reivindicacion 1: Un método para inhibir la pérdida de la agudeza visual asociada con la degeneracion macular relacionada con la edad (DMRE) en un paciente que posee DMRE o que se encuentra en riesgo de desarrollar DMRE debido a la presencia de un polimorfismo Y402H o de otra variante de riesgo, comprendiendo dicho método: a) identificar dicho polimorfismo Y402H u otra variante de riesgo en dicho paciente mediante i) la obtencion de una muestra de tejido de dicho paciente; y ii) el ensayo de dicha muestra de tejido en cuanto a la presencia del polimorfismo Y402H o de otra variante de riesgo, en donde la presencia del polimorfismo Y402H o de otra variante de riesgo indica un incremento en el riesgo de desarrollo de DMRE o en la progresion de la DMRE seca a la DMRE humeda; b) administrar a un paciente a quien se identifico en la etapa (a) precedente como poseyendo el polimorfismo Y402H u otra variante de riesgo una cantidad terapéuticamente efectiva de una composicion que comprende un inhibidor de C3-convertasa.
ARP060105794A 2005-12-22 2006-12-26 Inhibidores de c3-convertasa para la prevencion y el tratamiento de la degeneracion macular relacionada con la edad en pacientes con variantes de riesgo de factor h de complemento AR058749A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75313505P 2005-12-22 2005-12-22

Publications (1)

Publication Number Publication Date
AR058749A1 true AR058749A1 (es) 2008-02-20

Family

ID=38218828

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105794A AR058749A1 (es) 2005-12-22 2006-12-26 Inhibidores de c3-convertasa para la prevencion y el tratamiento de la degeneracion macular relacionada con la edad en pacientes con variantes de riesgo de factor h de complemento

Country Status (12)

Country Link
US (1) US20070149616A1 (es)
EP (1) EP1963529A2 (es)
JP (1) JP2009521506A (es)
KR (1) KR20080087814A (es)
CN (1) CN101346473A (es)
AR (1) AR058749A1 (es)
AU (1) AU2006330501B2 (es)
BR (1) BRPI0620249A2 (es)
CA (1) CA2631958A1 (es)
TW (1) TW200731984A (es)
WO (1) WO2007076437A2 (es)
ZA (1) ZA200805148B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2009015087A2 (en) * 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions and methods for treatment of trauma
CN101854916A (zh) * 2007-10-02 2010-10-06 博泰迪亚制药公司 由凝胶持续递送坎普他汀类似物
AU2008318316B2 (en) 2007-11-01 2015-08-06 University Of Iowa Research Foundation RCA locus analysis to assess susceptibility to AMD and MPGNII
US20110190221A1 (en) * 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
ES2879430T3 (es) 2012-11-15 2021-11-22 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
KR102314785B1 (ko) * 2015-04-21 2021-10-19 인제대학교 산학협력단 신규한 황반변성 진단용 마커 및 황반변성 진단방법
RU2770099C2 (ru) 2015-10-07 2022-04-14 Апеллис Фармасьютикалс, Инк. Схемы введения
EP3405577B8 (en) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
EP3423835B1 (en) * 2016-02-29 2023-10-25 Maintect GmbH Predictive markers useful in the treatment of wet age-related macular degeneration
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
AU2018249627A1 (en) 2017-04-07 2019-10-31 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043268A (en) * 1990-05-04 1991-08-27 The Trustees Of Princeton University Substrates and inhibitors for prenyl cysteine methyltransferase enzymes
JP2003511204A (ja) * 1999-10-21 2003-03-25 アルコン，インコーポレイティド テノン下薬剤送出
WO2001084149A2 (en) * 2000-04-29 2001-11-08 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
KR20050102653A (ko) * 2003-02-20 2005-10-26 알콘, 인코퍼레이티드 병적 눈 혈관신생 치료용 글루코코르티코이드 제제
NZ595305A (en) * 2005-02-14 2013-06-28 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of age-related macular degeneration
MX351152B (es) * 2005-10-08 2017-10-04 Potentia Pharmaceuticals Inc Compstatina y analogos de la misma para tratar trastornos oculares.

Also Published As

Publication number Publication date
WO2007076437A2 (en) 2007-07-05
BRPI0620249A2 (pt) 2011-11-08
TW200731984A (en) 2007-09-01
CN101346473A (zh) 2009-01-14
WO2007076437A3 (en) 2008-01-31
CA2631958A1 (en) 2007-07-05
KR20080087814A (ko) 2008-10-01
ZA200805148B (en) 2009-12-30
EP1963529A2 (en) 2008-09-03
US20070149616A1 (en) 2007-06-28
AU2006330501B2 (en) 2012-04-05
AU2006330501A1 (en) 2007-07-05
JP2009521506A (ja) 2009-06-04

Similar Documents

Publication Publication Date Title
AR058749A1 (es) Inhibidores de c3-convertasa para la prevencion y el tratamiento de la degeneracion macular relacionada con la edad en pacientes con variantes de riesgo de factor h de complemento
AR066292A1 (es) Tratamiento para la degeneracion macular relacionada con el envejecimiento utilizando inhibidores de factor d complementario
AR116859A2 (es) Métodos para tratar la esclerosis múltiple progresiva
WO2009012468A3 (en) Differential expression of micrornas in nonfailing versus failing human hearts
WO2020093006A8 (en) Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
Zhao et al. Effects of alpha-lipoic acid on spatial learning and memory, oxidative stress, and central cholinergic system in a rat model of vascular dementia
AR057631A1 (es) Composiciones y metodos para incrementar la sensibilidad a insulina
BRPI0518289A2 (pt) mÉtodos e composiÇÕes para o tratamento de desordens oculares
CO6390109A2 (es) Inhibidores de syk de imidazopirazina
EP1904111A4 (en) COMPOSITIONS AND METHODS FOR REDUCING MICRORNA EXPRESSION FOR THE TREATMENT OF NEOPLASIA
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
DE602006011607D1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
MX2009005941A (es) Ensayos de diagnostico complementario para terapia de cancer.
CL2017002825A1 (es) Formulaciones de tpp1 y métodos para tratar la enfermedad de cln2
MX2016016139A (es) Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5.
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
ATE446102T1 (de) Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii
ATE468849T1 (de) Idebenon zur behandlung von muskeldystrophien
Hatta et al. Nicotine reduced MMP‐9 expression in the primary porcine tenocytes exposed to cyclic stretch
Freese et al. Environmental enrichment reduces cocaine neurotoxicity during cocaine-conditioned place preference in male rats
WO2006047475A3 (en) Detection and analysis of ophthalmically-relevant fluorescent molecules
EP2716285A3 (en) New method for identifying compounds useful for treating and/or preventing diseases associated with bone loss
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
ATE550443T1 (de) Matrix-marker-modell und verfahren zur überprüfung und behandlung von rheumatischer arthritis
Röthig et al. Effects of nicotine on PTHrP and PTHrP receptor expression in rat coronary endothelial cells

Legal Events

Date Code Title Description
FB Suspension of granting procedure